Cursos

← vista completa

Publicado el 1 de septiembre de 2003 | http://doi.org/10.5867/medwave.2003.08.3333

Tratamiento adyuvante sistémico del cáncer de mama: etapas I y II

Systemic adjuvant treatment of breast cancer: stages I and II

Carlos Garbino

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Carlos Garbino

Grupo Oncológico del Uruguay

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Garbino C. Systemic adjuvant treatment of breast cancer: stages I and II. Medwave 2003;3(08):e3333 doi: 10.5867/medwave.2003.08.3333

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/09/2003

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, et al. National Institutes of Health consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst. 2001 Jul 4;93(13):979-89. | CrossRef | PubMed
  2. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Goldhiresh A, Glick JH, Gelber RD, Senn HJ : “Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst. 1998 Nov 4;90(21):1601-8. | CrossRef | PubMed
  3. St. Gallen 2001 News. Ed. Phillips Group Oncology Communications Co. PO Box 4024. Philadelphia, PA. USA, Decatron Digital Vision, Decatron Media AG | Link
  4. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jul;124(7):966-78. | PubMed
  5. Clark GM. Prognostic and predictive factors. En: Diseases of the breast. Philadelphia. PA. Lippincott Williams and Wilkins, 2000, 489–514.
  6. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J. The prognostic value of p53 and c – erb – B2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow -up of 14 – 30 years. Cancer. 2000 Feb 15;88(4):804-13. | CrossRef | PubMed
  7. Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A, et al. Prognostic significance of biologic mar–Kers in node–negative breast cancer patients: a prospective study. Breast Cancer Res Treat. 2000 Oct;63(3):181-92. | CrossRef | PubMed
  8. Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, et al. Correlation between p53, c–erb–B2 and topoisomerasa II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node–negative breast carcinomas: prognostic implications. J Pathol. 1999 Jan;187(2):207-16. | CrossRef | PubMed
  9. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev. 2000;(2):CD000485. | PubMed
  10. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: Population based study. BMJ. 2000 Feb 19;320(7233):474-8. | CrossRef | PubMed
  11. Ferrero JM, Ramaioli A, Formento JL, Francoual M, Etienne MC, Peyrottes I, et al. P53 determination alongside classical prognostic factors in node–negative breast cancer: an evaluation at more than 10 year follow-up. Ann Oncol. 2000 Apr;11(4):393-7. | CrossRef | PubMed
  12. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on Her–2, p 53 and BCL–2. Ann Oncol. 2000 Jun;11(6):647-63. | CrossRef | PubMed
  13. Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, et al. Disease–free survival advantage of adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with node–negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol. 2000 Sep;18(17):3125-34. | PubMed
  14. Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, et al. Low proliferative rate of invasive node- negative breast cancer predicts for a favourable outcome without adjuvant chemotherapy. Clin Breast Cancer. 2001 Jan;1(4):310-4; discussion 315-7. http://dx.doi.org/10.3816/CBC.2001.n.005 | PubMed
  15. Trock BJ, Yamauchi H, Brotzman M et al. c–erb–B2 as a prognostic factor in breast cancer (BC): a meta-analysis. Proc Am Soc Clin Oncol. 2000; 19:7
  16. Hayes DF, Yamauchi H, Stearns V et al.Should all breast cancers be tested for c–erb–B2? En: American Society of Clinical Oncology Educational Book. 36 th Annual Meeting. Alexandria, VA. USA. American Society of Clinical Oncology 2000, 257–265.
  17. Stål O, Borg A, Fernö M, Källström AC, Malmström P, Nordenskjöld B, et al. Erb B2 status and benefit from two or five years of adjuvant tamoxifen in post-menopausal early breast cancer. Ann Oncol. 2000 Dec;11(12):1545-50. | CrossRef | PubMed
  18. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, et al. Her 2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-15. J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8. | CrossRef | PubMed
  19. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, et al. neu/erb B–2 amplification identifies a poor–prognosis group of women with node negative breast cancer. J Clin Oncol. 1998 Apr;16(4):1340-9. | PubMed
  20. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma; analysis of 767 T1N0M0/ T2N0M0 patients with long-term follow-up. J Clin Oncol. 1993 Nov;11(11):2090-100. | PubMed
  21. Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer. J Clin Oncol. 1998 Sep;16(9):3129-36. | PubMed
  22. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000 Feb 1;60(3):636-43. | PubMed
  23. Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, et al. Invasion marker PAI–1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat. 1999 Mar;54(2):147-57. | CrossRef | PubMed
  24. Prechtl A, Harbeck N, Thomssen C, Meisner C, Braun M, Untch M, et al. Tumor-biological factors uPA and PAI–1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. Int J Biol Markers. 2000 Jan-Mar;15(1):73-8. | PubMed
  25. Thomssen C, Prechtl A, Meisner C, et al. Efficacy of adjuvant chemotherapy in node-negative breast cancer patients with elevated uPA and PAI–1. tumor S67, Abstract 133.
  26. Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med. 2000 Feb 24;342(8):525-33. | CrossRef | PubMed
  27. Abrams JS. Overview of the US consensus conference on adjuvant therapy for breast cancer. The Breast 2001; 10 (supplement 3): 139 – 146.
  28. Effects of adjuvant tamoxifen and cytotoxic therapy on mortalitv early breast cancer: an overview of 61 randomized trials among 28.896 women. N Engl J Med. 1988 Dec 29;319(26):1681-92. | CrossRef | PubMed
  29. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31.000 recurrences and 24.000 deaths among 75.000 women. Lancet. 1992 Jan 11;339(8785):71-85. | PubMed
  30. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998 May 16;351(9114):1451-67. | CrossRef | PubMed
  31. Fisher B, Digman J, Wiensd S, Wolmark N, wickerham DL. Duration of tamoxifent (TAM) therapy for primary breast cancer: 5 years versus 10 years (NSAPP) P-14. Proc Am Soc Clin Oncol. 1996; 15:113 (Abstract).
  32. Fischer B., Anderson s, Wolmark N, Tan-Chiu E. Chemoterapy with or without tamoxifen for patients with ER-negative breast cancer and negative nodes: Results from NSABP B-23. Proc Am Soc Clin Oncol. 2000; 19:72. (Abstract).
  33. Hutchins L, Green S, Ravdin P. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history fallow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102. Proc Am Soc Clin Oncol 1998; 17:1. (Abstract).
  34. Delozier T, Spielmann M, Mace-Lesech J et al.Short-term versus lifelong adjuvant tamoxifen in early breast cancer (EBC): A randomized trial (TAM-01). Proc Am Soc Clin Oncol 1997; 16: 1289.
  35. Gallen M, Alonso MC, Ojeda B et al. “Randomized multicentre trial comparing two different time-spans of adjuvant tamoxifen therapy (ATT) in women with operable node positive breast cancer”, Proc Am Soc Clin Oncol 1994; 13: 76(abst).
  36. Randomized trial of twa versus five years of adjuvant tamoxifen for postmenopausal early sta~e breast oancer. J Natl Cancer Inst. 1996 Nov 6;88(21):1543-9. | CrossRef | PubMed
  37. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, et al. Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast. Br J Cancer. 1996 Jul;74(2):297-9. | CrossRef | PubMed
  38. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst. 1996 Dec 18;88(24):1828-33. | CrossRef | PubMed
  39. CRC Trials Unit Birmingham. Adjuvant tamoxifen treatment offer more?(aTTom) Protocol. Birmingham: CRC Trials Unit.Clinical Research Block. Queen Elizabeth Hospital.
  40. Clinical Trial Service Unit, Radcliffe Infirmary, 0xford. Adjuvant tamoxifen longer against shorter (ATLAS). Protocol. April 1995. ATLAS Office,Clinical Trial Service Unit, Radcliffe lnfirmary,Oxford.(UK)
  41. Pritchard KI. Optimal endocrine therapy. The Breast 2001;10(Suppl 3):114—122
  42. Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsoh M,Gelber RD. Adjuvant Chemoendocrine therapy in postmenopausal breast cancer:cyclophosphamide, metothrexate and fluorouracil dose and schedule may make a difference. J Clin Oncol. 1998 Apr;16(4):1358-62. | PubMed
  43. Albain K,Green S,Osborne K. et al.Tamoxifen (T) versus cyclophosphamide adriamycin and 5-Fu plus either concurrent or sequential T in postmenopausal receptor (positive) or node (positive) breast cancer: A Southwest Onoology Group phase III intergroup trial (SWOG-8814,INT-0100) Proc Am Soc Clin Oncol l997;16:128a. (Abstract).
  44. Osborne CK :Effects of estrogen and antiestrogens on cell proliferation. Implications for treatment of breast cancer. Endocrine treatment in breast and prostate cancer. OWSBORNE ck, ED. Kluwer, Boston, Massachussets, USA 1988: 11-129.
  45. Ovarian ablation in early breast cancer: An overview of randomized. Trials. Lancet. 1996 Nov 2;348(9036):1189-96. | CrossRef
  46. Ovarian ablation for early breast cancer (Cochrane review). Cochrane Database Syst Rey 2000; 3:CD 000485.
  47. Early Breast Cancer Trialists’ Collaborative Group (EPCTCG) 2000 analysis overvlew results. Fifth Meeting of the Early Breast Canoer Trialists’ Collaborative Group. 2000 Oxford
  48. Peto R: Early Breast Cancer Trialists’ Collaborative Group Meeting. Oxford, October 2000.
  49. Adjuvant ovarian ablation CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet. 1993 May 22;341(8856):1293-8. | PubMed
  50. Ejlertsen B,Dombernowsky P, Mouridsen H. et al. Comparable effect of ovarian (OA) and CNF chemotherapy in premenopausal hormonal receptor positive breast cancer patients (prp) Proc Am Sao Clin Oncol l999; 18: 66a (Abstract)
  51. Jonat W. Zoladex (Goserelin) vs CMF as adjuvant therapy in pre/perimenopausal early node-positive breast oancer:preliminary efficacy, COL,and PMD results from the ZEBRA Study. Breast Can Res Treat 2000;1:20 (Abstract)
  52. Jakesz R, Gnant M,Hausmaninger H et al. Combination goserelin and tamoxifen is more effective than CMF in premenopausal patients with hormone-responsive tumors in a multicentre trial of the Austrian Breast Cancer Study Group (APCSG) Breast Cancer Res Treat 1999; 57:25.
  53. Roche H,Mihura J,de Cafontan B et al. Castration and tamoxifen versus chemotherapy. (FAC) for premenopausal, node and receptor-positive breast cancer patients: a randomized trial with a 7 years median follow-up. Proc Am Soc Clin Oncol 1996;15:117 (Abstract)
  54. Roche H,Keibrat P, Bonneterre J et al. Complete hormonal blockade versus chemotherapy in premenopausal early stage breast cancer patients (Pts) with positive hormone-reoeptors (HR+, ) and 1-3 node-positive (N+) tumor, results of the FASG 06 trial. Proc Am Soc Clin Oncol 2000;19:72a (Abstract).
  55. Davidson N,O’Neill A,Vukov A et al.Effect of chemo-hormonal therapy in premenopausal node (positive) receptor (positive) breast cancer: an Eastern Cooperative 0ncology Group Phase III Intergroup Trial (E 5128,INT-0101)Proc Am Soc Clin Oncol 1999; l8:67a (Abstract).
  56. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. Multicentre randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An Intergroup study. J Clin Oncol. 1998 Mar;16(3):994-9. | PubMed
  57. Boccardo F,Blamey R,Klijn J,Tominaga T,Duchateau L,Sylvester R. HRH-Agonist (LHRH-A) plus tamoxifen (TAM) versus LHRH-A alone in premenopausal women with advanced breast cancer (ABC) :Results of a meta-analysis of four trials#. Proc Am Soc Clin Oncol 1999;18:110a (Abstract).
  58. Kaufmann M,von Minckwitz G, for the German Adjuvant Breast Cancer Study Group (GABG). The emerging role of hormonal ablation as adjuvant therapy in node positive and node negative pre/perimenopausal patients. The Breast 2001; 10 (Suppl 3): 123-129.
  59. Randomized controlled trial of ovarian function supression plus tamoxifen versus the same endocrine the rapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. The Breast 2001;10 (Suppl 3): 130-138.
  60. Rutqvist LE. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A raridomized trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Group and the Gruppo Interdisciplinaire Valutazione Interventi in 0ncologia (GIVIO). Proc Am Soc Clin Oncol 1999;18:67a (Abstract)
  61. Zoladex (Goserelin) Vs CMF as adjuvant therapy in pre/perimenopausa1, node-positive,early breast cancer: Preliminary efficacy results from the ZEBRA study. Breast 2001;10:S30.
  62. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998 Sep 19;352(9132):930-42. | CrossRef | PubMed
  63. Carter CL, Allen C,Henson DE. Relation of tumour size, lymph node status and survival in 24,750 breast cancer cases. Cancer. 1989 Jan 1;63(1):181-7. | CrossRef | PubMed
  64. Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, et al. Prognosis and treatment of patients with breast turnors of one centimeter or less and negative axillary nodes. J Natl Cancer Inst. 2001 Jan 17;93(2):112-20. | CrossRef | PubMed
  65. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorrubicin-cyclo phosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer patients with tamoxifen-nonresponsive tumors: results from :the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 1990 8:1483—1496. | PubMed
  66. Carpenter JT, Velwz-Garcia E, Aron BS et al. Five years results of a randomized comparison of cyclophospharnide, doxorrubicin and fluorouracil for node-positive breast cancer. Proc Am Soc Clin Oncol 1994;13:68 (Abstraet 20s).
  67. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized tríal of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal wotnen with node positive breast cancer. J Clin Oncol. 1998 Aug;16(8):2651-8. | PubMed
  68. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and. older with tumors responsive to tamoxifen: Results from the Nationa1 Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990 Jun;8(6):1005-18. | PubMed
  69. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal treast cancer patients. J Clin Oncol. 1997 Apr;15(4):1385-94 | PubMed
  70. Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer. The International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000 Apr;18(7):1412-22. | PubMed
  71. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, et al. Tamoxifen and cheinotherapy for lymph node-negative,estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82. | CrossRef | PubMed
  72. Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, et al. Randomized trial of cyclophosphamide, methotrexate and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node positive, estrogen and/or progesterone receptor positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1997 Jun;15(6):2302-11. | PubMed
  73. Castiglione-Gertsch M, Price KN, Nasi ML, et al. Is the addition of adjuvant chemotherapy always necessary in node negative postmenopausal breast cancer patients who receive tamoxifen? First results of IBCSG trial IX. Proc Am Soc Clin Oncol 2000; 19: 73a (abst.281).
  74. Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, et al. Doxorubicin containing regimens for the treatment of Stage II breast cancer. The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989 May;7(5):572-82. | PubMed
  75. Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, et al. Adjuvant treatment of node-positive breast cancer with oyclophosphamide, doxorubicin, fluorouracil and vincristine versus cyclophosphamide, methotrexate and fluorouracil. Final report after a 16 year median follow-up duration. J Clin Oncol. 1996 Apr;14(4):1136-45. | PubMed
  76. Tormey DC, Gray R, Abeloff MD, Roseman DL, Gilchrist KW, Barylak EJ, et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. J Clin Oncol. 1992 Dec;10(12):1848-56. | PubMed
  77. Coombes RC, Bliss JM, Wils J, Morvan F, Espié M, Amadori D, et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal woman with axillary node-positive operable breast cancer: Results of a randomized trial. J Clin Oncol. 1996 Jan;14(1):35-45. | PubMed
  78. Lohrisch C, Di Leo A, Piccart MJ. Optimal adjuvant cytotoxic therapy for breast cancer. The Breast 2001;10 (Suppl 3):106-113.
  79. Basser RL. Optimal dose of chemotherapy in adjuvant treatment of breast cancer. The Breast 2001; 10 (Suppl 3): 96—100.
  80. Colleoni M,Gelber RD, Gelber S,Castiglione-Gertsoh M,Coates AS,Goldhirsch A: “How to improve timing and duration of adjuvant chemotherapy. The Breast 2001;10 (Suppl 3):101-105.
  81. Hryniuk W, Levine MN. Analysis of dose Intensity for adjuvant chemotherapy trials in Stage II breast cancer. J Clin Oncol. 1986 Aug;4(8):1162-70. | PubMed
  82. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11. | CrossRef | PubMed
  83. Bonneterre J, Roche H,Bremond A et al. Results of a randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk node-positive breast cancer patients. Proc Am Soc Clin Oncol 1998; 17:124a (abst 473).
  84. Henderson IC, Beny D, Demetri G et al. Improved disease-free and overall sur vival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node positive primary breast cancer. Proc Am Soc Clin Oncol 1998; 17:101a (abst 390ª)
  85. Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamicle regimen for the treatment of primary breast cancer. Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997 May;15(5):1858-69. | PubMed
  86. Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 1999 Nov;17(11):3374-88. | PubMed
  87. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, et al. Sequential dose-dense doxorubicin, paclitaxel and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy. J Clin Oncol. 1999 Jan;17(1):93-100. | PubMed
  88. Bonadonna G,Zambetti M,Valagusa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-years’ results. JAMA. 1995 Feb 15;273(7):542-7. | CrossRef | PubMed
  89. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erb B-2 expression and response to adjuvant chernotherapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 5;330(18):1260-6. | CrossRef | PubMed
  90. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erb B-2, p53 and efficacy of adjuvant therapy in lymph node positive breast cancer. J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60. | CrossRef | PubMed
  91. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erb B-2 and response to doxoruticin in pacients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst. 1998 Sep 16;90(18):1361-70. | CrossRef | PubMed
  92. Berry DA, Thor A, Cirrincione C, et al. Scientific inference and predictions; multiplicities and convincing stories: A case study in breast cancer therapy En: Statistics 5, Oxford UK. Oxford University Press. 1996, p 45—67.
  93. Paik S, Bryant J,Tan-Chiu E, et al. HER 2 and choice of adjuvant chemotherapy for invasive breast cancer. National Surgical Adjuvant Breast and Powel Project Protocol B-15 J Nat Cancer Inst 2000;92: 1991-1998.
  94. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, et al. Prognostic importance of c-erb B-2 expression in breast cancer. J Clin Oncol. 1992 Jul;10(7):1049-56. | PubMed
  95. Barnes DM, Smith S, Rubens RD. The relationship between outcome following adjuvant CMF and the presence of estrogen receptor and c-erb B-2 protein in 277 women with primary breast cancer. Breast Cancer Res Treat 1997;46:65 (abst 257).
  96. Phase III randomized study of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzuinab (Herceptin) in women with node positive breast cancer that overexpresses HER 2. National Surgical Adjuvant Breast and Bowel Project B-31.
  97. BCIRG 006: A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubiciri and cyclophosphamide followed by docetaxel and Herceptin (AC--TH) versus doce- taxel and platinum salt and Herceptin (TCH) in the treatment of node positive and high risk node negative adjuvant patients with operable breast cancer who overexpress HER 2 NEU. Breast Cancer International Research Group 006.
  98. HERA: Herceptin Adjuvant Trial | Link
  99. Perez EA. Adjuvant anti-HER 2 monoclonal antibody therapy - ready for breast cancer? The Breast 2001; 10 (Suppl 3 ):161—163.
  100. Davidson NE,Wolff AC. The use of anthracyclines and taxanes for adjuvant therapy of breast cancer. The Breast 2001:10 (Suppl 3): 90-95.
  101. Henderson IC: CALGB ria l9344NIH Dc an Adjuvant Therapy for Breast Cancer 2000 ; Bethesda,MD.USA.
  102. Adjuvant therapy for breast cancer. NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. 11512506
  103. Mamounas EF. Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary rodes NSABP B-28 protocol. NIH CDC on adjuvant therapy for breast cancer, 2000; Bethesda, MD.USA.
  104. Thomas E, Buzdar A, Theriault R et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of prospective randomized clinical trial. Proc Am Soc Clin Oncol. 2000;19:74 A (abst 285)
  105. BCIRG 001/TAX 316: A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus 5-Fluorouracil in combination with doxorubicin and cyclophosphamide (FAC) as adjuvant treatment of operable breast cancer patients with positive axillary Lymph nodes. Breast Cancer International Research Group TAX 316 protocol.
  106. Faculty members: “Ongoing trials of polychemotherapy for node—negative disease. En: Prognosis and treatment of node negative breast cancer. . Philadelphia, PA. USA, Ed.CE Gilmore, Phillips Group Oncology Comunications Co, 2001:p 18-19.
  107. Peters WP, Roaner G,Vredenburgh J et al. A prospective randomized camparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC NA-13. Proc Am Soc Clin Oncol 1999:18: 1ª. (abstr).
  108. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, et al. Tailored fluorauracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000 Oct 21;356(9239):1384-91. | CrossRef | PubMed
  109. Rodenhius S, Bontembal M, Beex L. et al. Randomized phase III study of high-dose chemotherapy with cyclophasphamide, thiotepa, and carboplatin in operable Breast cancer with 4 or more axillary lymph nodes. Proc Am Soc Clin Oncol 2000;19: 74a (abstr 286).
  110. Rodenhuis S, Huitema AD, van Dam FS, de Vries EG, Beijnen JH. High dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast Cancer. Cancer J. 2000 Apr;6 Suppl 2:S125-30. | PubMed
  111. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, et al. Randomised trial of highdose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary iymph-node involvement. Lancet. 1998 Aug 15;352(9127):515-21. | CrossRef | PubMed
  112. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, et al. Randomized trial of highdose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 2;92(3):225-33. | CrossRef | PubMed
  113. Mouridsen H,Andersen J,Anderson M et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMP combination with epirubicin. Proc Am Soc Clin Oncol 1999;18:68a (Abst 254).